share_log

Pfizer Presents Positive Data From Phase 2 Study of Ponsegromab in Patients With Cancer Cachexia

ファイザー社ががん悪液質を持つ患者を対象としたポンセグロマブの第2相試験からの好評なデータを発表

Benzinga ·  09/16 04:19
  • Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose evaluated at 12 weeks; ponsegromab was generally considered safe and well-tolerated at all dose levelsi
  • At the highest dose evaluated, improvements were seen from baseline in appetite and cachexia symptoms, physical activity, and muscle massi
  • Based on positive Phase 2 results, registration-enabling studies will start in 2025
これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする